Nutraceutical Citrulline in Pregnancy



Status:Recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:14 - 40
Updated:6/7/2018
Start Date:August 2016
End Date:December 2020

Use our guide to learn which trials are right for you!

Phase 1 Trial Citrulline and Type 2 Diabetes in Pregnancy

The purpose of this study is to determine if oral of L-citrulline (3 grams/day) for 3 weeks
provided in mid-pregnancy to pregnant women with type 2 diabetes will increase the plasma
L-arginine/ADMA ratio, lower maternal blood pressure and increase maternal levels of
placental growth factor (PlGF).

The pregnancy-specific syndrome preeclampsia is a leading cause of maternal and fetal
morbidity and mortality. The underlying cause of preeclampsia is unknown, however several
pre-existing maternal conditions are associated with an increased risk of preeclampsia
including: diabetes, hypertension, renal dysfunction, obesity and history of preeclampsia.
Specifically, the risk of preeclampsia is five times greater in women with diabetes.

Several lines of evidence indicate that endothelial dysfunction is a central feature of the
pathophysiology of preeclampsia. Asymmetric dimethylarginine (ADMA) is a methylated
metabolite of the amino acid L-arginine and an endogenous inhibitor of nitric oxide synthase
(NOS). High concentrations of ADMA contribute to endothelial dysfunction and ADMA inhibits
angiogenesis and arteriogenesis, activities important in pregnancy and deficient in
preeclampsia. ADMA concentrations are higher early in pregnancy among women who later develop
preeclampsia. This protocol describes a randomized placebo-controlled trial of L-citrulline
in 40 pregnant women with type 2 diabetes from approximately sixteen to nineteen weeks
gestation, to determine whether L-citrulline supplementation increases the plasma
L-arginine/ADMA ratio, lowers maternal blood pressure and increases a circulating marker of
placental function (placental growth factor PLGF).

Inclusion Criteria:

- Singleton pregnancy

- Type 2 diabetes with hemoglobin A1c <8

- Gestational age at randomization between 14 and 16 weeks based on clinical information

- Maternal age between 14 and 40 years

Exclusion Criteria:

- Chronic hypertension

- Major fetal anomaly

- Fetal demise

- Planned termination of the pregnancy

- Collagen vascular disease (autoimmune disease) on medication

- Renal disease

- Epilepsy or other seizure disorder

- Active or chronic liver disease

- Heart disease, known illicit drug or alcohol abuse during current pregnancy

- Already taking L-citrulline as a supplement (1gram/day or more)
We found this trial at
1
site
300 Halket St.
Pittsburgh, Pennsylvania 15213
1-866-MyMagee (696-2433)
Phone: 412-641-6005
Magee-Womens Hospital of UPMC Magee-Womens Hospital of UPMC is a world-class center for both women's...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials